Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma
Public ClinicalTrials.gov record NCT01277523. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 mcg and 5 mcg Once Daily) Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Adolescents (12 to 17 Years Old) With Severe Persistent Asthma
Study identification
- NCT ID
- NCT01277523
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 392 participants
Conditions and interventions
Conditions
Interventions
- tiotropium high dose Drug
- placebo Drug
- tiotropium low dose Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2010
- Primary completion
- Sep 30, 2013
- Completion
- Sep 30, 2013
- Last update posted
- Oct 19, 2014
2011 – 2013
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.456.01004 Boehringer Ingelheim Investigational Site | Stockton | California | — | — |
| 205.456.01008 Boehringer Ingelheim Investigational Site | Normal | Illinois | — | — |
| 205.456.01003 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 205.456.01007 Boehringer Ingelheim Investigational Site | Columbia | Missouri | — | — |
| 205.456.01002 Boehringer Ingelheim Investigational Site | Bellevue | Nebraska | — | — |
| 205.456.01001 Boehringer Ingelheim Investigational Site | Rockville Centre | New York | — | — |
| 205.456.01005 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 205.456.01006 Boehringer Ingelheim Investigational Site | Summerville | South Carolina | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01277523, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2014 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01277523 live on ClinicalTrials.gov.